Guilherme Nader Marta, Advanced Clinical Fellow – Dana-Farber Cancer Institute, shared a post on LinkedIn:
“DESTINY-Breast06 trial out in The New England Journal of Medicine
T-DXd improved median PFS to 13.2 mos vs 8.1 mos w/ chemo (HR 0.62, CI 0.51–0.74) in HR+/HER2-low mBC after 1-2 lines of ET
Consistent results in the HER2-ultralow population (HR 0.78, CI 0.5-1.2)
OS data immature.”
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Authors: Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce A. O’Shaughnessy, Hans Wildiers, Jean-Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Seock-Ah Im, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, and Giuseppe Curigliano.
Source: Guilherme Nader Marta/X